AFP and hepatocellular carcinoma: Additionally, GAAD (Cobas), GALAD, (Cobas), and GALAD (μTASWAKO) algorithms showed greater sensitivity for HCC across all disease stages when compared with individual serum biomarkers (AFP, AFP-L3, and PIVKA-II) alone.